NCT02604511View on ClinicalTrials.gov

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
Waldenstrom's Macroglobulinemia
Interventions
DRUG

Ibrutinib

Trial Locations (2)

02114

Massacusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER